Carotid intima-media thickness and ezetimibe: The end of a misunderstanding?

Current Vascular Pharmacology

Volumn 9, Issue 4, 2011, Pages 381-384

  Paraskevas, Kosmas I ^a   Veith, Frank J ^b   Mikhailidis, Dimitri P ^c  

^a RED CROSS HOSPITAL   (Greece)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AORTA STENOSIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CAROTID INTIMA MEDIA THICKNESS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; INTERNAL CAROTID ARTERY; KIDNEY FUNCTION; MONOTHERAPY; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CAROTID INTIMA-MEDIA THICKNESS; CAROTID STENOSIS; CHOLESTEROL, LDL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959980432     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111796197198     Document Type: Editorial

References (35)

1. Brott TG, Hobson RW 2nd, Howard G, et al.; CREST Investigators. Stenting vs. endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11-23.
2. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/ AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SV S Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery Developed in Collaboration With the American Academy of Neurology and Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2011; 57: e16-94.
3. Silver FL, Mackey A, Clark WM, et al.; for the CREST Investigators. Safety of stenting and endarterectomy by symptomatic status in the carotid revascularization endarterectomy vs. stenting trial (CREST). Stroke 2011; 42: 675-80.
4. Abbott AL. Medical (non-surgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009; 40: e573-83.
5. Naylor AR, Gaines PA, Rothwell PM. Who benefits most from intervention for asymptomatic carotid stenosis: patients of professionals? Eur J Vasc Endovasc Surg 2009; 37: 625-32.
6. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke 2010; 41: e11-7.
7. Liapis CD, Bell PF, Mikhailidis DP, et al.; ESVS Guidelines Collaborators. ESVS Guidelines: section A-prevention in patients with carotid artery stenosis. Curr Vasc Pharmacol 2010; 8: 673-81.
8. Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
9. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 2008; 6: 237-9.
10. Zhou Q, Liao JK. Pleiotropic effects of statins-basic research and clinical perspectives. Circ J 2010; 74: 818-26.
11. Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: a LDL-associated action or one more pleiotropic effect of statins? Atherosclerosis 2010; 213: 8-20.
12. Landmesser U, Bachlmann F, Mueller M, et al. Simvastatin vs. ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63.
13. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006; 27: 1182-90.
14. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-8.
15. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? an update after 4 years. Curr Vasc Pharmacol 2011; 9: 62-86.
16. Sarigianni M, Katsiki N, Mikhailidis DP. Ezetimibe in diabetes: more than cholesterol lowering? Curr Med Res Opin 2010; 26: 2517-20.
17. Stein EA. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem 2008; 54: 940-2.
18. Carotid Atorvastatin Study in Hyperlipidemic Post-menopausal Women: a Randomized Evaluation (CASHMERE). Available at: http://www.clinicaltrials.gov/ct/show/NCT00163163?order=1. [Accessed on March 23, 2011].
19. Paraskevas KI, Mikhailidis DP, Veith FJ. Optimal statin type and dosage for vascular patients. J Vasc Surg 2011; 53: 837-44.
20. Harrison DG, Brown WV, Raggi P. Enhanced hype. Am J Cardiol 2008; 102: 368-9.
21. Toutouzas P, Richter D. Carotid intima-media thickness (cIMT): a useful clinic tool or research luxury? Another view of the ENHANCE trial. Angiology 2008; 59(2 Suppl): 77S-79S.
22. Duivenvoorden R, Vergeer M, Kastelein JJ. Niacin compared with ezetimibe. N Engl J Med 2010; 362: 1046-7.
23. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone vs. statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52: 2198-205.
24. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media Thickness and Overall arterial Rigidity (VYCTOR) study. J Clin Pharmacol 2009; 49: 838-47.
25. van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005; 95: 264-6.
26. Howard WJ. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Nutr Metab Cardiovasc Dis 2010; 20: 295-300.
27. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL And LDL Treatment Strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55: 2721-6.
28. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361: 2113-22.
29. Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
30. Avellone G, Di Garbo V, Guarnotta V, et al. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Int Angiol 2010; 29: 514-24.
31. Crouse JR 3rd, Raichlen JS, Riley WA, et al.; METEOR Study Group. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-53.
32. Bots ML, Palmer MK, Dogan S, et al.; METEOR Study Group. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med 2009; 265: 698-707.
33. Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol 2010; 105: 1802-8.
34. Loomba RS, Arora R. Statin therapy and aortic stenosis: a systematic review of the effects of statin therapy on aortic stenosis. Am J Ther 2010; 17: e110-114.
35. Cannon CP, Giugliano RP, Blazing MA, et al.; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin vs. simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-32.